Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvonralimab + paclitaxel + cisplatin
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This neoadjuvant chemotherapy regimen is a combination therapy being evaluated for the treatment of locally advanced or fertility-desiring cervical cancer. It consists of the bifunctional biologic QL1706 (iparomlimab and tuvonralimab), which simultaneously targets the immune checkpoint proteins PD-1 and CTLA-4, combined with the standard chemotherapy agents paclitaxel and cisplatin. QL1706, developed by Qilu Pharmaceutical, is designed to enhance tumor-specific immune activation by dual blockade of inhibitory pathways on T-lymphocytes. Paclitaxel acts as a microtubule stabilizer, while cisplatin is a platinum-based DNA-damaging agent. The regimen is currently being studied in a Phase 2 umbrella trial (NCT06878222) sponsored by the Obstetrics & Gynecology Hospital of Fudan University to shrink tumors prior to surgery and potentially improve fertility-sparing outcomes.
- Brand names
- Qibeian
- Other names
- Iparomlimab and Tuvonralimab + paclitaxel + cisplatinQL1706 + paclitaxel + cisplatinIparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNA
Beyond the preview
Go deeper on iparomlimab + tuvonralimab + paclitaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvonralimab + paclitaxel + cisplatin.